Log In
Print
BCIQ
Print
Print this Print this
 

M2SR, REDEE FLU

  Manage Alerts
Collapse Summary General Information
Company FluGen Inc.
DescriptionReplication-deficient live attenuated vaccine based on the deletion of the influenza A virus matrix protein 2 (M2) gene
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Viral vaccine
Latest Stage of DevelopmentPreclinical
Standard IndicationInfluenza virus
Indication DetailsVaccinate against H5N1 avian influenza infection
Regulatory Designation
Partner Arecor Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today